RE: AVA6000 - remarkably consistent…13 Jun 2022 14:56
"Could it be then, that with adverse side effects eliminated and with dosing being done at levels known to be effective, patients would derive no additional benefit if dosing were raised to a higher, second level? Has dosing another cohort at a second level of escalation been deemed inappropriate?"
It's a trial. It's designed to answer those exact questions. Patients might derive benefit from a higher dose - if you don't test it, you'll not learn as much from the trial. I'll patiently wait for the results, whenever they might be.